Added to YB: 2026-01-28
Pitch date: 2026-01-26
TEM [neutral]
Tempus AI, Inc.
-11.67%
current return
Author Info
No bio for this author
Company Info
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
Market Cap
$11.6B
Pitch Price
$67.88
Price Target
97.30 (+62%)
Dividend
N/A
EV/EBITDA
-77.06
P/E
-54.93
EV/Sales
11.04
Sector
Life Sciences Tools and Services
Category
growth
TEM | Tempus AI Q3 2025 Financial Highlights
TEM (earnings): Healthcare AI platform w/ 84.7% revenue growth to $334M, driven by M&A (Ambry, Paige). Genomics +117%, data +26%. First positive adj EBITDA $2M. Paige Predict launched for AI-powered pathology diagnosis. High-margin data licensing is key value driver. DCF intrinsic value $54.75 vs current $64.84. Risk: M&A-driven growth may decelerate, integration challenges, regulatory risks. 9.1x PS ratio reasonable given growth but not cheap.
Read full article (9 min)